Immunohistochemistry and Microsatellite Instability Analysis in Molecular Subtyping of Colorectal Carcinoma Based on Mismatch Repair Competency

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2016 Feb 18

PMID 26885030

Citations 32

Authors

Lin Yuan

Yayun Chi

Weixiang Chen

Xiaochen Chen

Ping Wei

Weiqi Sheng

Xiaoyan Zhou

Daren Shi

Affiliations

Soon will be listed here.

Abstract

Mismatch repair defective (MMRd) colorectal carcinoma (CRC) is a distinct molecular phenotype of colorectal cancer, including 12% of sporadic CRC and 3% of Lynch Syndrome. In order to investigate the clinicopathological characteristics of MMRd colorectal carcinoma, and to find the most effective method for preliminary screening, 296 CRC fulfilled revised Bethesda Guideline (RB) were selected from 1450 CRCs to perform both IHC staining for MLH1, MSH2, MSH6, PMS2 and MSI analysis. Sixty-eight tumors were classified as MSI-H by MSI test. Colorectal carcinomas with MSI-H were prone to be proximal located, poorly differentiated, and relatively early staged, with infrequent metastasis to lymph node as well as to distant organs, compared with MSS ones. All of the 68 MMRd CRCs presented abnormal expression of at least one mismatch repair protein (MMRP), with 48 concurrent negative of MLH1 and PMS2, 14 concurrent negative of MSH2 and MSH6, 4 isolated negative of MSH6, 1 isolated negative of PMS2, and 1 concurrent negative of 4 MMRPs. All of the MLH1 negative tumors also showed abnormal expression of PMS2. All of the MSH2 negative cases also presented negative expression of MSH6. The sensitivity and specificity of the 2-antibody IHC test contained only PMS2 and MSH6 for screening for MMRd CRC were 100% and 98.2% respectively, exactly the same as that of the 4-antibody IHC test with all of the 4 MMRPs. The diagnostic accordance rate of the 2-antibody approach and MSI analysis was 98.6%. In conclusion, MMRd CRC has characteristic clinicopathological features different from MSS CRCs. The 2-antibody IHC approach containing MSH6 and PMS2 is the most easy and effective way to detecting MMR deficiency in CRC.

Citing Articles

In silico splicing analysis of the PMS2 gene: exploring alternative molecular mechanisms in PMS2-associated Lynch syndrome.

Munteanu C, Marian C, Chirita-Emandi A, Puiu M, Trifa A BMC Genom Data. 2024; 25(1):100.

PMID: 39592919 PMC: 11600730. DOI: 10.1186/s12863-024-01281-3.

BRAF-mutant mismatch repair deficient invasive colon cancer regressing to sessile serrated lesion.

Matsuno K, Miyamoto H, Shimoda M, Gushima R, Nagaoka K, Ohuchi M Clin J Gastroenterol. 2024; 17(5):904-909.

PMID: 39003365 DOI: 10.1007/s12328-024-02006-w.

Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer.

Heregger R, Huemer F, Steiner M, Gonzalez-Martinez A, Greil R, Weiss L Cancers (Basel). 2023; 15(20).

PMID: 37894457 PMC: 10605634. DOI: 10.3390/cancers15205090.

Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer.

Kim Y, Aiob A, Kim H, Suh D, Kim K, Kim Y Biomedicines. 2023; 11(10).

PMID: 37893065 PMC: 10603999. DOI: 10.3390/biomedicines11102691.

A simplified two-marker immunohistochemistry strategy for Lynch syndrome screening in endometrial cancer patients.

Aiob A, Kim Y, Kim K, Kim H, Kim Y, Kim D Obstet Gynecol Sci. 2023; 66(6):537-544.

PMID: 37839795 PMC: 10663397. DOI: 10.5468/ogs.23124.

References

Jenkins M, Hayashi S, OShea A, Burgart L, Smyrk T, Shimizu D . Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007; 133(1):48-56. PMC: 2933045. DOI: 10.1053/j.gastro.2007.04.044. View

Shia J, Zhang L, Shike M, Guo M, Stadler Z, Xiong X . Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Mod Pathol. 2012; 26(1):131-8. PMC: 3793326. DOI: 10.1038/modpathol.2012.138. View

Watson N, Grieu F, Morris M, Harvey J, Stewart C, Schofield L . Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn. 2007; 9(4):472-8. PMC: 1975100. DOI: 10.2353/jmoldx.2007.060162. View

Wahlberg S, Schmeits J, Thomas G, Loda M, Garber J, Syngal S . Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res. 2002; 62(12):3485-92. View

Shia J, Klimstra D, Nafa K, Offit K, Guillem J, Markowitz A . Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol. 2004; 29(1):96-104. DOI: 10.1097/01.pas.0000146009.85309.3b. View

Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M . Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut. 1999; 45(3):409-15. PMC: 1727633. DOI: 10.1136/gut.45.3.409. View

Ogino S, Nosho K, Kirkner G, Kawasaki T, Meyerhardt J, Loda M . CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2008; 58(1):90-6. PMC: 2679586. DOI: 10.1136/gut.2008.155473. View

WARD R, Meagher A, Tomlinson I, OConnor T, Norrie M, Wu R . Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 2001; 48(6):821-9. PMC: 1728324. DOI: 10.1136/gut.48.6.821. View

Halford S, Sawyer E, Lambros M, Gorman P, MacDonald N, Talbot I . MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol. 2003; 201(3):389-94. DOI: 10.1002/path.1453. View

10.

Acharya S, Wilson T, Gradia S, Kane M, Guerrette S, Marsischky G . hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A. 1996; 93(24):13629-34. PMC: 19374. DOI: 10.1073/pnas.93.24.13629. View

11.

Buttin B, Powell M, Mutch D, Babb S, Huettner P, Bocker Edmonston T . Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet. 2004; 74(6):1262-9. PMC: 1182090. DOI: 10.1086/421332. View

12.

Umar A, Koi M, Risinger J, Glaab W, Tindall K, Kolodner R . Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res. 1997; 57(18):3949-55. View

13.

Blake C, Tsao J, Wu A, Shibata D . Stepwise deletions of polyA sequences in mismatch repair-deficient colorectal cancers. Am J Pathol. 2001; 158(5):1867-70. PMC: 1891934. DOI: 10.1016/S0002-9440(10)64143-0. View

14.

Muller W, Burgart L, Krause-Paulus R, Thibodeau S, Almeida M, Edmonston T . The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study. Fam Cancer. 2003; 1(2):87-92. DOI: 10.1023/a:1013840907881. View

15.

Aarnio M, Mustonen H, Mecklin J, Jarvinen H . Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med. 1998; 30(1):75-80. DOI: 10.3109/07853899808999387. View

16.

Halvarsson B, Anderson H, Domanska K, Lindmark G, Nilbert M . Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers. Am J Clin Pathol. 2008; 129(2):238-44. DOI: 10.1309/0PP5GDRTXUDVKAWJ. View

17.

Jass J, Do K, Simms L, Iino H, Wynter C, Pillay S . Morphology of sporadic colorectal cancer with DNA replication errors. Gut. 1998; 42(5):673-9. PMC: 1727100. DOI: 10.1136/gut.42.5.673. View

18.

Young J, Simms L, Biden K, Wynter C, Whitehall V, Karamatic R . Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol. 2001; 159(6):2107-16. PMC: 1850604. DOI: 10.1016/S0002-9440(10)63062-3. View

19.

Wright C, Stewart I . Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol. 2003; 27(11):1393-406. DOI: 10.1097/00000478-200311000-00001. View

20.

Mangold E, Pagenstecher C, Friedl W, Fischer H, Merkelbach-Bruse S, Ohlendorf M . Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol. 2005; 207(4):385-95. DOI: 10.1002/path.1858. View